

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE NINE MONTHS ENDED 31 MARCH 2023**

<b>THE GROUP</b>				
	Unaudited Quarter Ended 31 Mar 2023	Unaudited Quarter Ended 31 Mar 2022	Unaudited 9 Months Ended 31 Mar 2023	Unaudited 9 Months Ended 31 Mar 2022
	Rs'000	Rs'000	Rs'000	Rs'000
<b>Turnover</b>	784,410	791,256	2,239,823	2,259,920
Earnings Before Interests, Taxation, Depreciation and Amortisation (EBITDA)	158,322	183,100	464,378	546,317
Depreciation and amortisation	(44,748)	(36,170)	(125,762)	(101,033)
<b>Earnings Before Interests and Taxation (EBIT)</b>	113,574	146,930	338,616	445,284
Net finance cost	(15,593)	(14,189)	(44,044)	(44,009)
<b>Profit before taxation</b>	<b>97,981</b>	<b>132,741</b>	<b>294,572</b>	<b>401,275</b>
Taxation	(16,530)	(22,456)	(49,494)	(69,316)
<b>Profit after tax</b>	<b>81,451</b>	<b>110,285</b>	<b>245,078</b>	<b>331,959</b>
<b>Attributable to:</b>				
Equity holders	81,451	110,285	245,078	331,959
<b>Earnings per share</b>				
Earnings attributable to equity holders	81,451	110,285	245,078	331,959
Number of shares in issue ('000)	569,941	569,941	569,941	569,941
<b>Earnings per share (Rs/Cs)</b>	0.14	0.19	0.43	0.58

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 31 MARCH 2023**

<b>THE GROUP</b>		
	Unaudited As at 31 Mar 2023	Audited As at 30 June 2022
	Rs'000	Rs'000
<b>ASSETS</b>		
Non-current assets	2,616,124	2,453,081
Current assets	865,587	843,057
<b>TOTAL ASSETS</b>	<b>3,481,711</b>	<b>3,296,138</b>
<b>EQUITY AND LIABILITIES</b>		
Equity attributable to:		
Equity holders	1,306,600	1,061,522
<b>TOTAL EQUITY</b>	<b>1,306,600</b>	<b>1,061,522</b>
Non-current liabilities	1,304,956	1,250,959
Current liabilities	870,155	983,657
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>3,481,711</b>	<b>3,296,138</b>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY AS AT 31 MARCH 2023**

<b>Attributable to equity holders</b>				
	Issued Capital	Revaluation reserve	Retained Earnings	Total Equity
	Rs'000	Rs'000	Rs'000	Rs'000
At 1 July 2021	289,801	265,494	269,900	825,195
Profit for the period	-	-	331,959	331,959
<b>At 31 March 2022</b>	<b>289,801</b>	<b>265,494</b>	<b>601,859</b>	<b>1,157,154</b>
At 1 July 2022	289,801	345,241	426,480	1,061,522
Profit for the period	-	-	245,078	245,078
<b>At 31 March 2023</b>	<b>289,801</b>	<b>345,241</b>	<b>671,558</b>	<b>1,306,600</b>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED 31 MARCH 2023**

<b>THE GROUP</b>		
	Unaudited 9 Months Ended 31 Mar 2023	Unaudited 9 Months Ended 31 Mar 2022
	Rs'000	Rs'000
Net Cash flows from operating activities	304,299	424,581
Net Cash flows used in investing activities	(234,875)	(97,806)
Net Cash flows used in financing activities	(239,406)	(160,607)
<b>(Decrease)/Increase in cash and cash equivalent</b>	<b>(169,982)</b>	<b>166,168</b>
<b>MOVEMENT IN CASH AND CASH EQUIVALENT</b>		
At the beginning of the period	398,220	234,852
Movement during the period	(169,982)	166,168
<b>At the end of the period</b>	<b>228,238</b>	<b>401,020</b>

**NOTES**

The abridged financial statements for the 9 months ended 31 March 2023 are unaudited and have been prepared using the same accounting policies as in the audited financial statements for the year ended 30 June 2022.

The above results are a consolidated view of the operations of C-Care Darné, C-Care Wellkin and C-Lab including C-Care North Ltd and Centre de Radiothérapie de l'Océan Indien Ltd, wholly owned subsidiaries of C-Care (Mauritius) Ltd (the "Group").

The Group has seen an increase in its normal activities and maintained a good performance despite the decrease in covid related activities and increase in operating costs compared to same period last year.

The Board of Directors of C-Care (Mauritius) Ltd accepts full responsibility for the accuracy of the information contained in this report.

By Order of the Board

**CIEL Corporate Services Ltd**  
**Company Secretary**

Date: 9 May 2023

BRN: C07002054

This report is pursuant to Rule 17 of the Development & Enterprise Market and Securities Act 2005.

Copies of the Unaudited Condensed Financial Statements are available to the public free of charge at the Company's registered office: 5<sup>th</sup> Floor, Ebène Skies, rue de l'Institut, Ebène. The statement of direct and indirect interests of insiders pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007 is available free of charge at the registered office of the Company.



**C-CARE (MAURITIUS) LTD**

---

## **NOTICE**

### **UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED 31 MARCH 2023**

The Board of Directors of C-Care (Mauritius) Ltd (the "Company") wishes to inform its shareholders and the public in general that the Unaudited Condensed Consolidated Financial Statements of the Company and its Subsidiaries for the nine months ended 31 March 2023 have been approved on 9 May 2023.

The Unaudited Condensed Consolidated Financial Statements of the Company and its Subsidiaries will be published on the website of the Company on <https://c-care.com/mu/investors-corner/> and copies of same are available to the public free of charge at the registered office of the Company at 5<sup>th</sup> Floor, Ebène Skies, Rue de l'Institut, Ebène.

By Order of the Board

**CIEL Corporate Services Ltd**  
Company Secretary

9 May 2023

This Notice is given pursuant to DEM Rule 17.3 and the Securities Act 2005.

The Board of Directors of C-Care (Mauritius) Ltd accepts full responsibility for the accuracy of the information contained in this Notice.

**BRN: C07002054**